Atovaquone is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Prevention of Pneumocystis jirovecii pneumonia in patients who are intolerant to TMP/SMX
- Oral treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (second or third line)
- Prevention and treatment of malaria (in combination with proguanil: see separate module)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Toxoplasmosis treatment alone (limited data with atovaquone 750 mg four times a day in adults)
- Toxoplasmosis treatment in combination with pyrimethamine or sulfadiazine
- Babesiosis (in combination with azithromycin)
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: September 29, 2018
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Atovaquone
ID - 540038
A1 - Pham,Paul,Pharm.D.
AU - Smith,Janessa,Pharm.D., BCPS
Y1 - 2018/09/29/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540038/all/Atovaquone
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -